Swiss pharma giant Roche’s (ROG: SIX) regulatory application for emicizumab in hemophilia A has been given priority review status by the US Food and Drug Administration.
Roche has applied to market the monoclonal antibody as a once-weekly subcutaneous treatment for adult, adolescent and child patients who have developed inhibitors to factor VIII.
The development of such inhibitors, which occurs in up to a third of cases, limits treatment options and increases the severity and impact of the disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze